Untitled

Toquet, Claire; Néel, Jean; Guillou, Louis; Renaudin, Karine; Hamy, A.; Heymann, Marie‐Françoise; Simon-Valla, Sophie; Borgne, J. Le; Maugard, Christine M.; Fiche, Maryse

doi:10.1023/a:1020187211376

Cited by 41 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Ki-67 has been widely used as a proliferative marker in many different tumors, including GISTs [ 19 - 21 ]. However, Ki-67 is expressed throughout the cell cycle except in the G0 phase.…”

Section: Discussionmentioning

confidence: 99%

PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors

Shin¹,

Hyeon²,

Lee³

et al. 2015

J Pathol Transl Med

View full text Add to dashboard Cite

Background:Counting mitoses is subjective and time-consuming. The adjunctive diagnostic utility of a recently reported mitotic marker, phosphohistone H3 (PHH3), was investigated in gastrointestinal stromal tumors (GISTs).Methods:We reviewed 77 GISTs for several proliferative indices. These included the mitotic count per 50 high power fields (HPFs), the immunohistochemical Ki- 67 labeling index and the immunohistochemical PHH3 mitotic index (MI). For comparison, Spearman’s rank correlation and interclass correlation coefficient were used.Results:Mitotic counts ranged from 0–138 (mean, 7.57±2.34) and the PHH3 MI ranged from 0–126 per 50 HPFs (mean, 9.61±2.27). We found a positive correlation between mitotic counts and PHH3 MI (r=0.810, p<.001). The inter-observer correlation coefficient for three participants was 0.975 for mitotic counts and 0.940 for the PHH3 MI. When using the PHH3 MI instead of mitotic counts in the Armed Forces Institute of Pathology (AFIP) stratification criteria, 10 cases were reclassified. In one patient with a mitotic count of 2 and a PHH3 MI of 6 per 50 HPFs, distant metastasis occurred.Conclusions:In GISTs, the PHH3 MI correlated adequately with mitotic counts and can be used as a useful adjunctive to count mitotic figures efficiently.

show abstract

“…Ki-67 has been widely used as a proliferative marker in many different tumors, including GISTs [ 19 - 21 ]. However, Ki-67 is expressed throughout the cell cycle except in the G0 phase.…”

Section: Discussionmentioning

confidence: 99%

PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors

Shin¹,

Hyeon²,

Lee³

et al. 2015

J Pathol Transl Med

View full text Add to dashboard Cite

show abstract

“…With the exception of methylated E-cahedrin, all were less reliable than mitotic activity in predicting survival. Several studies demonstrated that the proliferative marker Ki-67 and its analogs, MIB-1 and Ki-S5, significantly correlate with clinical course and prognosis [30, 32, 37]. However, data regarding the involvement of cell cycle regulatory proteins, cyclins, CDKs and CDIs in GISTs and their clinical implication is limited.…”

Section: Discussionmentioning

confidence: 99%

The Cyclin-Dependent Kinase Inhibitor, p27kip1, Has No Correlation with the Malignant Potential of GIST

Shirin

Kravtsov²,

Shahmurov³

et al. 2007

Digestion

View full text Add to dashboard Cite

Background: Tumor size and mitotic activity are characteristically associated with the malignant potential and prognosis of gastrointestinal stromal tumors (GIST). However, since neither small tumor size nor low mitotic activity can rule out malignancy, additional factors that may predict malignant behavior have been suggested. Aim: To evaluate the correlation between the cyclin-dependent kinase inhibitor (CDI), p27^kip1, expression and the malignant potential of GIST. Methods: Serial sections were evaluated by immunohistochemistry after staining with antibodies against p27/Kip1 and Ki-67 in surgical material obtained from 36 patients with GIST. p27^kip1 staining intensity and the percentage of positive cells were investigated for association with the malignancy risk, pathological features, overall survival, and disease-free survival. Histologic grade was assigned by spindle vs. epithelioid cell histology, mucosal invasion, tumor cell necrosis or atypia and the number of mitoses. Results: In the multivariate model, p27^kip1 expression was not significantly associated with any of the variables examined except Kit protein-CD117 (r = 0.37, p = 0.03). Comparative evaluation of p27^kip1 expression in GIST cells revealed higher levels of p27^kip1 in patients who died compared to those who survived (2.04 ± 0.54 vs. 1.3 ± 0.99, p = 0.1). Conclusion: The CDI p27^kip1 was not associated with malignancy of GISTs and did not serve as a predictor of survival.

show abstract

“…[3033] Ki67 (MIB-1) is a marker of proliferation and can be assessed in resected GISTs and EUS-guided FNA specimens but its ability to predict GIST behavior remains unclear and in need of further study. [4849] The PDGFRA gene mutation is another useful tool in the evaluation of cKIT negative GISTs. Up to 14% of GISTs are cKIT negative, but are positive for PDGFRA gene mutation.…”

Section: On-site Cytopathology Evaluationmentioning

confidence: 99%

When to puncture, when not to puncture: Submucosal tumors

Salah

Faigel

2014

Endosc Ultrasound

View full text Add to dashboard Cite

Subepithelial masses of the gastrointestinal (GI) tract are a frequent source of referral for endosonographic evaluation. Subepithelial tumors most often appear as protuberances in the GI tract with normal overlying mucosa. When there is a need to obtain a sample of the mass for diagnosis, endoscopic ultrasound (EUS) - guided fine-needle aspiration (FNA) is superior to other studies and should be the first choice to investigate any subepithelial lesion. When the decision is made to perform EUS-guided FNA several technical factors must be considered. The type and size of the needle chosen can affect diagnostic accuracy, adequacy of sample size and number of passes needed. The use of a stylet or suction and a fanning or standard technique during EUS-guided FNA are other factors that must be considered. Another method proposed to improve the efficacy of EUS-guided FNA is having an on-site cytopathologist or cytotechnician. Large or well-differentiated tumors may be more difficult to diagnose by standard EUS-FNA and the use of a biopsy needle can be used to acquire a histopathology sample. This can allow preservation of tissue architecture and cellularity of the lesion and may lead to a more definitive diagnosis. Alternatives to FNA such as taking bite-on-bite samples and endoscopic submucosal resection (ESMR) have been studied. Comparison of these two techniques found that ESMR has a significantly higher diagnostic yield. Most complications associated with EUS-FNA such as perforation, infection and pancreatitis are rare and the severity and incidence of these adverse events is not known. Controversy exists as to the optimal method in which to perform EUS-FNA and larger prospective trials are needed.

show abstract

Untitled

Cited by 41 publications

References 15 publications

PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors

PHH3 as an Ancillary Mitotic Marker in Gastrointestinal Stromal Tumors

The Cyclin-Dependent Kinase Inhibitor, p27kip1, Has No Correlation with the Malignant Potential of GIST

When to puncture, when not to puncture: Submucosal tumors

Contact Info

Product

Resources

About